How Rousseau was paid
$17.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Jon RousseauPresident and Chief Executive Officer | $1,316,717 | — | $6,000,015 | $5,999,997 | $3,893,750 | $630,980 | $17,841,460 |
| Jim MattinglyFormer Executive Vice President and Chief Financial Officer | $106,154 | — | — | — | — | $437,304 | $543,457 |
| Jennifer PhippsExecutive Vice President and Chief Financial Officer | $469,265 | — | $1,500,004 | $1,499,999 | $927,084 | $47,699 | $4,444,051 |
| Bob BarnesPresident, Community Living | $450,015 | $187,500 | — | — | $430,650 | $1,770 | $1,069,935 |
| Lisa NalleyChief of Staff and Senior Vice President, Human Resource | $349,680 | — | $800,010 | $800,004 | $445,000 | $1,571 | $2,396,266 |
| Scott GreenwellExecutive Vice President and President, PharMerica | $249,041 | $274,000 | $375,005 | $162,966 | — | — | $1,436,755 |
| Jennifer YowlerFormer President, PharMerica and Senior Vice President, Sales and Account Management | $440,003 | $5,000 | $400,014 | $400,002 | $104,758 | $1,754 | $1,351,531 |
What changed and why
- $618MAdjusted EBITDA for fiscal 2025 grew to $618 million compared to $460 million in 2024.
- $2.8BRevenue for the company increased by $2.8 billion, or 28.2%, to $12.9 billion.
- $17.8MCEO Jon Rousseau received total compensation of $17,841,460 for fiscal 2025.
- The CEO to median employee pay ratio was calculated to be 382 to 1.
- Annual cash incentives utilized a balanced scorecard focusing on profitability, revenue growth, and a quality index.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.